Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis.
Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis.
复制标题
DOI：
10.1371/journal.pone.0152564
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Lu H
中科院分区：
文献类型：
--
作者：
Bai S;Song Y;Huang X;Peng L;Jia J;Liu Y;Lu H
为了回应关于他汀类药物的使用与帕金森病（PD）风险之间关系的持续争论，我们对观察性研究进行了系统回顾和荟萃分析，以检查其相关性。我们使用电子数据库进行文献综述，并辅以人工检索，以确定潜在相关的病例对照或队列研究。使用随机效应模型计算总结相对风险（RR）和95%置信区间（CI）。还进行了敏感性和亚组分析。纳入了11项研究（5项病例对照和6项队列），共有3，513，209名参与者和21，011例PD病例。他汀类药物的使用与PD风险降低相关，汇总RR为0.81（95% CI 0.71-0.92）。敏感性分析证明了结果的稳健性。亚组分析表明，无论是研究设计还是研究区域都不会显著影响效应估计值。然而，调整年龄或性别的亚组研究比未调整的分析有更大的负相关性（年龄校正RR 0.75，95% CI 0.60-0.95;年龄未校正RR 0.86，95% CI 0.75-0.99和性别校正RR 0.76，95% CI 0.59-0.98;性别未校正RR 0.85，95% CI 0.79-0.92）。这项系统性综述的结果表明，他汀类药物的使用与PD风险降低相关。然而，在得出强有力的结论之前，应该进行随机对照试验和更多的观察性研究。
In response to the ongoing debate over the relationship between the use of statins and the risk of Parkinson's disease (PD), we performed a systematic review and meta-analysis of observational studies to examine their association. We conducted a review of the literature using electronic databases supplemented by a manual search to identify potentially relevant case-control or cohort studies. Summary relative risk (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Sensitivity and subgroup analyses were also conducted. Eleven studies (five case-control and six cohort) with a total of 3,513,209 participants and 21,011 PD cases were included. Statin use was associated with a lower risk of PD, with a summary RR of 0.81 (95% CI 0.71–0.92). Sensitivity analysis demonstrated the robustness of results. Subgroup analyses showed that neither study design nor study region significantly influenced the effect estimates. However, subgroup studies adjusted for age or sex had a greater inverse association than did unadjusted analyses (age-adjusted RR 0.75, 95% CI 0.60–0.95; age-unadjusted RR 0.86, 95% CI 0.75–0.99 and sex-adjusted RR 0.76, 95% CI 0.59–0.98; sex-unadjusted RR 0.85, 95% CI 0.79–0.92). Results of this systematic review suggest that statin use is associated with a reduced PD risk. However, randomized controlled trials and more observational studies should be performed before strong conclusions are drawn.